TABLE 3.

Insulin sensitivity, β-cell function, and body weight in the TRIPOD and PIPOD studies

Variable		Baseline TRIPOD (period 1)	Baseline PIPOD (period 2)	End PIPOD (period 3)	P value (2 vs. 1)*	P value (3 vs. 2)*
TRIPOD troglitazone group (n = 27)
Si (min · μU−1 · ml−1 · 10−4)		2.38 ± 1.52	2.81 ± 2.09	2.50 ± 2.56	0.23	0.57
AIRg (μU · ml−1 · min−1)		453 ± 283	479 ± 309	392 ± 207	0.60	0.13
DI		913 ± 518	1,095 ± 607	878 ± 598	0.24	0.12
Weight (kg)		69.1 ± 10.9	73.0 ± 11.0	75.0 ± 11.2	<0.0001	0.006
TRIPOD placebo group (n = 32)
Si (min · μU−1 · ml−1 AIRg (μ10−4)		2.79 ± 2.32	2.24 ± 1.24	2.16 ± 1.34	0.16	0.72
AIRg (μU · ml−1 · min−1)		593 ± 554	382 ± 285	484 ± 357	0.03	0.13
DI		1125 ± 687	754 ± 542	953 ± 678	0.003	0.14
Weight (kg)		68.3 ± 8.8	69.4 ± 8.0	72.3 ± 9.6	0.15	0.0004

Data are means ± SD from 59 women who had IVGTTs performed at enrollment into to TRIPOD (period 1), at enrollment into PIPOD (period 2, equivalent to end of postdrug washout period for TRIPOD), and end of postdrug washout period in PIPOD (period 3), so that all results were obtained remote from any acute drug effects.

^*By paired t test.